| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10914907 | Molecular Oncology | 2012 | 5 Pages |
Abstract
⺠Diverse laboratory methodologies are available for various analytes, often making test development problematical. ⺠Integral marker clinical trials and standard-of-care applications must employ regulatory-compliant biomarkers. ⺠The Institute of Medicine of the National Academies in the United States has produced a comprehensive review of omics-based tests. ⺠Understanding of aberrations along molecular pathways and of intratumoral heterogeneity are key to successful use of biomarkers.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Stanley R. Hamilton,